SmartLens develops contact lenses for monitoring and treating glaucoma.

Murat Baday

Savas Komban

Sevda Agaoglu

Ismail Emre Araci

Ahmet Taylan Yazici

SmartLens

Smartlens is a clinical-stage company developing innovative technologies for diagnosing and treating glaucoma, a leading cause of irreversible blindness.

Its flagship product, miLens, is a groundbreaking, non-invasive contact lens-based device designed to monitor intraocular pressure (IOP), the primary and only treatable risk factor for glaucoma. miLens addresses a significant unmet need in glaucoma management that has persisted since the 1950s.

Strong clinical results for miLens were presented at the 2023 and 2024 American Glaucoma Society meetings, and commercialization is planned for 2025.

miLens features a unique, electronics-free sensor technology developed and patented by Smartlens, with protection in over 40 countries. Additionally, the portfolio includes THERmic, an advanced non-invasive drug delivery technology that enhances treatment effectiveness by offering personalized therapies. This technology helps prevent disease progression and lays the foundation for a new generation of therapies.

Smartlens has received investments from prominent institutions, venture capital firms, Stanford University, and key opinion leaders. In recognition of its achievements, Smartlens was honored with the “Outstanding Innovation in Medical Technology and Life Sciences” award at the 2021 High-Tech Awards by Octane. The company’s technologies have also been recognized by prestigious sources such as Nature Medicine, Fortune, BBC, and ABC News.

Smartlens envisions a world where glaucoma no longer robs individuals of their vision and quality of life.

Graphene Ventures

Boutique Venture Partners

Sophia Innovation Capital

Ambit Health Ventures

Device of Tomorrow Capital

Stanford University

WS Investments

Plaisance Capital

3E Bioventures

Smartlens

It was a remarkable experience to speak at the Paving the Path for #Glaucoma's Future panel during the American Glaucoma Society meeting. The Inaugural #Innovation Summit showcased cutting-edge advancements in glaucoma, including Smartlens’ #miLens, enabling #remote IOP monitoring for a more effective approach to managing glaucoma. The overwhelmingly positive feedback, support, and encouragement from numerous glaucoma specialists further validate our efforts to bring miLens to the market. Thank you to everyone who contributed to making this event a great success! Analisa Arosemena, MD Lorraine Provencher Christine Funke Eydie Miller-Ellis Thomas W. Samuelson Gilad Litvin David Esposito Davinder S Grover, MD Deborah Nysather

#innovationinhealthcare #preventblindness #ophthalmology 
#remotepatientmonitoring #glaucomaawareness #earlydiagnosis

Join us at the 2024 AGS Annual Meeting in Huntington Beach, CA, where Smartlens' breakthroughs with miLens, enabling remote IOP monitoring, will be showcased at the Inaugural #Glaucoma Innovation Summit: Paving the Path For Glaucoma's Future, hosted by the American Glaucoma Society.

#remotepatientmonitoring #ophthalmology #innovationinhealthcare 
#preventblindness #personalizedhealthcare  #earlydiagnosis 

https://lnkd.in/eRC97US

Excited to share Smartlens’ progress toward commercialization at #Glaucoma360 by Glaucoma Research Foundation. Join us for an engaging session on Glaucoma Beyond The Office moderated by Drs. Barbara Wirostko MD, FARVO and Lama Al-Aswad, MD, MPH. Reflecting on the insightful discussions from last year's panel on Optimeyezing Eye Care.

#innovationinhealthcare  #preventblindness #eyehealth #glaucoma #personalizedmedicine #ophthalmology #optometry #glaucomaawareness

Thank you, Jennifer Heimlich from Well+Good for an amazing article on the potential of #wearable #devices transforming #healthcare which also showcases the potential of Smartlens’ products. 

As she mentioned, with miLens, those who need it can easily and comfortably check their #eye #pressure a few times a month or year, and ideally catch any changes before #glaucoma progresses to the point where they lose their vision.

Here are some highlights from the article:

- According to a 2023 study from Yale University, more than a quarter of Americans now use a wearable health-tracking device.

- The medical wearables market had an estimated value of $31.06 billion globally in 2023, and is projected to reach $63.68 billion by 2028, according to a July report conducted by market research firm Infogence Global Research. 

-      According to Unity Stoakes, president and co-founder of StartUp Health: “Every device in and around our lives can become a tool to improve our health. Not just the things we wear, like watches, but the cars we drive, the couches we sit on, the pillows we use, the refrigerators where we store our food,” “If today’s most amazing innovators do it right, they will design health into the fabric of our lives.”

Let's embrace this cultural shift towards #proactivehealth and #personalizedmedicine , ensuring a brighter, healthier future for all.

#healthcareinnovation #digitalhealth #wearabletech  #eyehealth     #glaucomaawareness  #preventblindness #ophthalmology #optometry

Smartlens is delighted to announce that our CEO, Savas Komban, will be taking the stage at #Eyecelerator @ AAO 2023, spotlighting the #innovative future of #ophthalmology. Join us in exploring groundbreaking advancements and engaging with industry visionaries driving change. We are committed to contributing meaningful dialogue and are excited to share our latest developments in #EyeCare.

#InnovationInHealthcare #VisionCare #PersonalizedMedicine #PreventBlindness #Glaucoma #EyeHealth

Congratulations to RESI JPM San Francisco Innovator’s Pitch Challenge (IPC) finalist, Smartlens! CEO and Founder, Savas Komban will pitch to a panel of #investor judges, live and in-person, on Tuesday, January 9. Applications are open until 11/22: https://bit.ly/3l4WTKc 
#RESIJPM #RESIJPM24 #RESISANFRAN

Smartlens (#LSIUSA24 Innovator) is aiming to prevent blindness due to Glaucoma and address the biggest challenges in Glaucoma management.

Glaucoma is the leading cause of irreversible blindness worldwide and more than 50% of the people suffering from Glaucoma are undiagnosed.

Smartlens aims to significantly improve patient outcomes and how doctors manage the disease by providing an efficient and convenient way of IOP monitoring and personalized treatments.

The company’s flagship product miLens, is the first device capable of measuring IOP anywhere, at any time. miLens is similar to a daily contact lens and will significantly improve Glaucoma management as a non invasive, electronics free, ultra sensitive, and easy to use device.

🌟 Smartlens recently achieved several major milestones including:

• Announced positive clinical results in a study focused on evaluating the accuracy and comfort of miLens. The study reported a significant and statistically strong correlation between IOP measurements obtained with miLens and those obtained using Goldmann applanation tonometry (GAT) in twenty-five individuals.

• Closed an oversubscribed $6.1M Series A equity financing round led by Ambit Health Ventures, joined by Stanford University, Graphene Ventures, Sophia Innovation Capital, Plaisance Capital Management, 3E Bioventures, Boutique Venture Partners and Wilson Sonsini Investments alongside doctors, industry veterans and key opinion leaders. The funding will be used to advance regulatory clearance for miLens, a novel, electronics-free, soft contact lens for monitoring diurnal intraocular pressure

Congratulations to the Smartlens team on these major milestones!

We’re excited to announce that Smartlens CEO, Savas Komban has been selected to present at LSI USA ‘24 in Dana Point, California March 18-22, 2024.

Thank you, Medical Device and Diagnostics, for highlighting Smartlens' dedication to creating user-friendly ophthalmic devices. We believe in harnessing advanced technologies to ensure #exceptional #user #comfort.

The #miLens, our innovative soft contact lens, is designed with a microfluidic system. This allows patients to easily monitor their intraocular pressure from the comfort of their homes, bridging a significant gap in #glaucoma care. 

By intentionally removing electronics from our design, we've created a lens as comfortable and familiar as a corrective contact lens, emphasizing the "Keep It Super Simple" (KISS) approach while solving a significant and unmet medical need. 

As Leonardo Da Vinci wisely said, “Simplicity is the ultimate sophistication”

#innovationinhealthcare  #glaucoma #ophthalmology #preventblindness 
#eyehealth #optometry #medicaldevice #digitalhealth #remotepatientmonitoring 

https://lnkd.in/gJrJ6TZc

Metric
Company Name	SmartLens
Symbol
MSH ID	HEALTH:SMARTLENS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Devices
Country	US
Stage
Employee Count	1
Website	smartlens.health
LinkedIn	smartlens-health
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

SMAR

HEALTH:SMARTLENS

SmartLens

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue